IRIS
ARPINO, GRAZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.112
EU - Europa 1.396
AS - Asia 805
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
SA - Sud America 1
Totale 4.359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.076
IT - Italia 834
SG - Singapore 445
CN - Cina 274
NL - Olanda 137
IE - Irlanda 97
DE - Germania 91
FI - Finlandia 77
FR - Francia 40
GB - Regno Unito 37
IN - India 34
VN - Vietnam 34
CI - Costa d'Avorio 33
CA - Canada 32
UA - Ucraina 29
BE - Belgio 8
ES - Italia 7
PK - Pakistan 6
RO - Romania 6
SE - Svezia 6
HK - Hong Kong 5
AL - Albania 3
AU - Australia 3
BZ - Belize 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EG - Egitto 3
EU - Europa 3
LT - Lituania 3
IR - Iran 2
MY - Malesia 2
RS - Serbia 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
CL - Cile 1
GR - Grecia 1
HR - Croazia 1
ID - Indonesia 1
JP - Giappone 1
MC - Monaco 1
MK - Macedonia 1
MT - Malta 1
MX - Messico 1
NG - Nigeria 1
NO - Norvegia 1
PL - Polonia 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 4.359
Salva come PNG Salva come JPEG
Città #
Chandler 486
Singapore 373
Napoli 138
Amsterdam 129
Millbury 117
Naples 99
Ashburn 98
Santa Clara 96
Princeton 87
Beijing 72
Nanjing 68
Boston 56
Jacksonville 43
Des Moines 41
Wilmington 35
Dong Ket 32
Milan 30
Ottawa 28
Pune 27
Nanchang 25
Lawrence 22
Hebei 20
Rome 18
Palermo 15
Tianjin 15
Redwood City 13
Dearborn 12
Seattle 12
Bologna 11
Shenyang 11
Jiaxing 10
Changsha 9
Dublin 9
Pomigliano d'Arco 9
Munich 8
Boardman 7
Fairfield 7
Helsinki 7
Salerno 7
Ann Arbor 6
Casoria 6
Formia 6
Kronberg 6
Kunming 6
Massa di Somma 6
Rozzano 6
Sant'Agnello 6
Washington 6
Castellammare Di Stabia 5
Dallas 5
Duncan 5
Edinburgh 5
Hong Kong 5
Kortrijk 5
Los Angeles 5
Portici 5
Buffalo 4
Falls Church 4
Granada 4
Guangzhou 4
Indiana 4
Menfi 4
Norwalk 4
Nova Milanese 4
Paris 4
Redmond 4
Shenzhen 4
Villaricca 4
Bari 3
Battipaglia 3
Belize City 3
Campobasso 3
Caserta 3
Craiova 3
Florence 3
Genoa 3
Lahore 3
Lappeenranta 3
London 3
Luco dei Marsi 3
Menlo Park 3
Pellezzano 3
San Jose 3
San Mateo 3
Serravalle Scrivia 3
Shanghai 3
Springfield 3
Tirana 3
Angri 2
Augusta 2
Brno 2
Caivano 2
Carpi 2
Castelnuovo del Garda 2
Catania 2
Fort Worth 2
Frattamaggiore 2
Groningen 2
Hangzhou 2
Hanoi 2
Totale 2.528
Salva come PNG Salva come JPEG
Nome #
null 223
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 94
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 90
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility 78
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine 74
null 67
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 65
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 65
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 61
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 52
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 52
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 52
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 51
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 50
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 49
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 49
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 48
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 48
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. 47
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. 47
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 47
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: A retrospective study 46
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 46
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 46
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 45
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 44
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 44
The importance of using strain derived criteria for detection of subclinical cardiotoxicity in breast cancer patients undergoing anthracycline and trastuzumab 44
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 42
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. 41
A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”, 41
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 41
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 41
The continuing role of breast fine-needle aspiration biopsy after the introduction of the IAC Yokohama System For Reporting Breast Fine Needle Aspiration Biopsy Cytopathology 41
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 41
Features of aggressive breast cancer 40
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 40
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study 39
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 39
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 39
Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy: Results from a joinpoint regression analysis. 38
Tumor characteristics and prognosis in familial breast cancer 37
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 37
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 36
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer 35
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 34
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study 34
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 34
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 34
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 33
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. 33
Treatment of triple negative brest cancer (TNBC): current options and future perspectives. 33
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 33
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 33
Core curriculum. Oncologia clinica 33
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 33
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 33
HEAD TO HEAD COMPARISON OF STANDARD ECHO DOPPLER AND 3D SPECKLE TRACKING ECHOCARDIOGRAPHY IN DETECTION OF SUBCLINICAL ANTHRACYCLINE CARDIOTOXICITY IN BREAST CANCER 32
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 32
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 31
Capitolo 4 - Terapia Medica 31
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance 31
Home Exercise Program is an effective tool in improving upper limb function and quality of life in breast cancer survivors: A retrospective observational study 31
Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report 30
Prognostic and predictive factors in breast cancer, an evidence-based medicine approach 30
GMO-Gestione Malattie Oncologiche in Regione Campania. 30
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study 30
Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network 30
Prevalence of Sarcopenia in Women with Breast Cancer 29
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice? 29
Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. 29
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. 29
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study 29
Core curriculum. Oncologia clinica 28
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET) 27
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. 27
Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications 27
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511] 26
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. 26
Triple-negative breast cancers: Biomarkers and outcomes 26
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). 26
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 26
Health-care costs associated with breast cancer management 25
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. 25
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 25
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? 24
Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]] 24
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 24
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients 23
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. 23
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. 22
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 22
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 21
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis 21
Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. 21
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. 21
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes 21
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy. 21
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. 21
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study 20
Totale 3.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.161
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.161
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020217 0 0 0 0 0 27 16 22 9 45 54 44
2020/2021318 4 10 31 31 32 45 40 12 51 7 21 34
2021/2022696 9 2 14 4 5 20 7 26 104 98 151 256
2022/20231.126 122 91 30 109 129 135 18 96 152 154 67 23
2023/2024721 34 114 71 39 25 87 11 70 18 22 133 97
2024/2025699 247 205 47 75 123 2 0 0 0 0 0 0
Totale 4.625